These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 22901346

  • 1. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.
    J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
    [Abstract] [Full Text] [Related]

  • 2. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
    Baldwin DS, Loft H, Dragheim M.
    Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 7. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 8. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.
    Boulenger JP, Loft H, Florea I.
    J Psychopharmacol; 2012 Nov; 26(11):1408-16. PubMed ID: 22495621
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD.
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH.
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [Abstract] [Full Text] [Related]

  • 12. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
    Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV.
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
    [Abstract] [Full Text] [Related]

  • 13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 15. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.
    Baldwin DS, Hansen T, Florea I.
    Curr Med Res Opin; 2012 Oct; 28(10):1717-24. PubMed ID: 22978748
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH, Cutler AJ, Richards C, Lasser R, Geibel BB, Gao J, Sambunaris A, Patkar AA.
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [Abstract] [Full Text] [Related]

  • 19. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR.
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [Abstract] [Full Text] [Related]

  • 20. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
    Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, EMBOLDEN I (Trial 001) Investigators.
    J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.